← Human Trials & Peer-Reviewed Studies
The Effect of Simulation-Based Oxytocin Induction Training on Midwifery Students' Knowledge and Anxiety Levels
Plain-language guide to NCT07788495: not phased randomized trial of Oxytocin, 80 participants. Who took part, design and what was measured.
Key Facts
- Registry ID
- NCT07788495
- Phase
- not phased
- Status
- completed
- Start
- 2024-11-11
- Completion (planned or actual)
- 2025-05-26
- Participants
- 80 (actual)
- Design
- randomized, single-blind, other
- Conditions studied
- Simulation-based Midwifery Education; Oxytocin Induction
- Results posted
- not yet
What This Study Did, in Plain Language
What Was Tested
In this not phased trial, researchers set out to test Oxytocin.
This randomized controlled study was conducted to evaluate the effect of simulation-based oxytocin induction training on midwifery students' knowledge and anxiety levels.
The study population consisted of third-year midwifery students enrolled in the Faculty of Health Sciences at Istanbul Medipol University during the spring semester of the 2024-2025 academic year.
Eligible students who volunteered to participate were randomly assigned to an intervention group or a control group.
It had two arms (groups): Theoretical Training + Simulation-Based Training (experimental) and Theoretical Training (active comparator).
Participants in this arm received theoretical training on oxytocin induction. In addition to the theoretical training, they received simulation-based oxytocin induction training using high-fidelity simulation and a standardized patient.
Participants in this arm received theoretical training on oxytocin induction and did not receive the additional simulation-based training.
The registry classes the interventions as behavioral.
Who Took Part
80 actual participants took part.
It was open to people of any sex.
Healthy volunteers could join, not only people with the condition.
Examples of who could join: Being enrolled as a third-year undergraduate student in the Department of Midwifery, Faculty of Health Sciences, Istanbul Medipol University, during the spring semester of the 2024-2025 academic year. Having successfully completed the Childbirth and Postpartum Period course. Having successfully completed the Childbirth and Postpartum Period Clinical Practice course. Having a cumulative grade point average of 2.70 or higher. Volunteering to participate in the study.
The full record lists 6 inclusion and 3 exclusion criteria; among the exclusions: not meeting one or more of the inclusion criteria; declining to participate in the study; not providing written or verbal informed consent.
How the Study Was Run
Design: randomized, parallel-group and single-blind.
The participants were allocated by chance, so the Oxytocin group and the comparison group should start out alike.
Groups ran in parallel: each of the participants stayed in one arm throughout.
In this single-blind Oxytocin study one party knew the assignments and the other did not.
Those kept unaware of assignments: outcomes assessor.
It started in 2024-11-11 with completion listed for 2025-05-26.
It ran at 1 site in Turkey (Türkiye).
Its stated primary purpose is other.
What Was Measured
Researchers chose this as the main measure: Change in Oxytocin Induction Knowledge Score (time frame: At baseline, before theoretical training, and 5 weeks after theoretical training).
It also tracked 1 secondary outcome, for example Change in State Anxiety Score.
What This Means in Plain Language
Put simply, this is a not phased, randomized trial of Oxytocin in 80 people.
The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.
More context: the Oxytocin compound page, all human trials.
Our Notes on the Compound
Oxytocin: A peptide hormone with established obstetric medical uses and a less settled role in research on behavior, sexual function and appetite.
Related Pages
Source: ClinicalTrials.gov record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.